MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

Search

Evotec AG

Cerrado

SectorFinanzas

7.33 0.27

Resumen

Variación precio

24h

Actual

Mínimo

7.12

Máximo

7.42

Métricas clave

By Trading Economics

Ingresos

-1.2M

-41M

Ventas

36M

221M

Margen de beneficios

-18.46

Empleados

4,740

EBITDA

58M

-45M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+39.37% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.1B

Apertura anterior

7.06

Cierre anterior

7.33

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Evotec AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 jun 2024, 13:17 UTC

Charlas de Mercado

Evotec's Profit Outlook Looks Gloomy -- Market Talk

Comparación entre iguales

Cambio de precio

Evotec AG previsión

Precio Objetivo

By TipRanks

39.37% repunte

Estimación a 12 Meses

Media 10.23 EUR  39.37%

Máximo 12.1 EUR

Mínimo 7 EUR

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Evotec AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

5.818 / 7.348Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Evotec AG

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.